

Test information is available on our website: **PreventionGenetics.com**



All testing must be ordered by a qualified Healthcare Provider

THIS FORM MUST ACCOMPANY ALL SPECIMENS

Prenatal - Healthcare Providers Statement

NOTE: This statement must be signed by the ordering Healthcare Provider indicating the following informed consent has been provided to the patient.

Visit our Prenatal Testing web page for details and limitations regarding prenatal testing.

LAST (FAMILY) NAME	T (FAMILY) NAME FIRST NAME MI DATE OF BIRTH (
TEST(S) REQUESTED						
-	red and applies to all co	าses of ongoing r	oregnancy.			
My signature below indicate	_	avanatal taat fay OA muy				
·	tal specimen is required for any p					
, , , , , , , , , , , , , , , , , , , ,	est Code #990), familial positive o	•	·			
 I understand that a back up cel prenatal tests. 	l culture is required for NGS and s	trongly recommended	for other			
of insurance coverage given the	ng will proceed when all test reque time-sensitive nature of many of (see page 4 of the Prenatal Test F	f these tests. Holds for	-			
 I have explained the purpose of genetic counseling to my patie 	the prenatal testing I have requent.	ested, and I have provide	ed appropriate			
· I have given the opportunity fo	the patient to ask questions.					
-	vritten or verbal informed conser limitations of the testing and the		ults).			
HEALTHCARE PROVIDER SIGNATURE	PRINTED NAME		DATE			
Retention of Unused DNA Statement of PreventionGenetics' general policy is to reduce additional testing in the future and saves of DNA specimens can also be used for qualic conditions I was tested for, and any related diapproval by an Institutional Review Board or in order to retain excess DNA beyond 60 days be discarded 30 days after testing is completed.	ain all excess DNA from patient test ensiderable phlebotomy and shipping by control measures or for research of seases or conditions, which may inclu- as otherwise permitted under applic s. If patient specimen was collected in	g costs to the patient and on genetic variants associ ude further testing of my re able law. New York (NY) law	healthcare system. Excess ated with the diseases or stained samples, subject to w requires patient consent			
I authorize PreventionGenetics to retain un purposes described above.	used DNA for potential future testir	ng ordered by my Healtho	care Provider and for the			
PATIENT OR LEGAL REPRESENTATIVE SIGNATURE	PRINTED NAME		DATE			

PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences Corporation.



Test information is available on our website: **PreventionGenetics.com**

PREVENTIONGENETICS USE ONLY

All testing must be ordered by a qualified Healthcare Provider

THIS FORM MUST ACCOMPANY ALL SPECIMENS

Test Description, Methods, and Limitations

regarding prenatal testing.

See specific full test description at PreventionGenetics.com for information about clinical features, genetics, indications for testing, test procedure, test description, clinical sensitivity, analytical validity, analytical limitations, and turnaround times. Please visit our Prenatal testing web page for details and limitations

Purpose of Testing (mark all that apply)
Diagnosis
Other (please describe):

Results

- Positive genetic testing results may mean a person carries or has the condition or disease being tested. Often this means Pathogenic or Likely Pathogenic genetic variation(s) has/have been identified. Consulting with a Physician or Genetic Counselor prior to and after completion of testing is recommended to learn the full meaning of the results and their implications.
- Negative results may mean, within limitations of the test, no Pathogenic or Likely Pathogenic genetic variations were identified. However, consultation with a Medical Geneticist, Genetic Counselor or Specialty Provider is recommended should the patient or Ordering Provider have additional questions or concerns.
- Uncertain results may mean a Variant(s)
 of Uncertain Significance (VUS) was/were
 identified. It is not clear if these variants
 are linked to the patient's phenotype or are
 associated with disease.
- Pathogenic variants, Likely Pathogenic variants, and Variants of Uncertain Significance in genes thought to be

associated with the clinical phenotype will always be reported.

- We recommend the patient stay in touch with their Healthcare Provider(s) to discuss any updated information regarding results and our interpretation(s). An ordering Healthcare Provider can request a re-interpretation from us by contacting our laboratory.
- · Upon request, PreventionGenetics will provide raw data for sequencing tests to authorized recipients. The data will be provided once testing is complete and final reports have been released. PreventionGenetics does not supply software for data review and interpretation.

Incidental Findings

- Testing could reveal information unrelated to the patient's clinical features. If we learn of information which could be medically actionable, we will relay this information to the Healthcare Provider(s) for discussion
- · If we learn family relationships are not as expected (for example, due to possible specimen mix-up or possible non-paternity), this information will be relayed to the Healthcare Provider(s) for discussion, but will not be included in the patient's report.

Who Has Access to Test Results?

- The patient tested or his/her Authorized Representative (Preventions Genetics requires a signed patient authorization form which is available upon request).
- Any person specifically authorized in writing by the patient tested or his/her Authorized Representative.
- A researcher for medical research or public health purposes if the research is done under federal or state law governing clinical and biological research, or if the identity of the individual is not disclosed.
- The ordering Healthcare Provider or an Authorized Agent or employee of the

Healthcare Provider, if they are authorized to obtain the test results, provide patient care, treatment, or counseling, and need to know the information to perform or improve the patient care, treatment, or counseling.

- The hospital or Healthcare Provider for purposes of quality assurance.
- Federal, state, or county health agencies, as they may be authorized.

Confidentiality

We take confidentiality and patient privacy very seriously. We follow confidentiality laws related to protected health information and are CAP, CLIA, and ISO certified laboratory.

Risks

- Learning about test results can be stressful and upsetting for the patient and their family.
- The patient and/or patient's family may have concerns about genetic discrimination, including health insurance, life insurance, employment and long-term disability. These should be addressed according to federal and state laws. The Genetic Information Non-discrimination Act (GINA) prohibits the use of genetic information for discrimination in health insurance and employment. We recommend patients discuss specific concerns with their Healthcare Provider.
- As genetic knowledge and understanding changes over time, it is possible a patient's result may be reclassified.
 This could lead to changes in medical management recommendations or care of family members.

Right to Genetic Counseling

The patient has the right to genetic counseling prior to having testing and again when results have been issued.



PreventionGenetics.com



All testing must be ordered by a qualified Healthcare Provider

>>>

A completed online order **OR** paper TRF and labeled specimen is required to initiate testing.

PRENATAL TEST REQUISITION

	Positive control samples			INSTRU	CTIONS			
	Prenatal Healthcare Prov	•	ıded)		_	,		Ithcare Provider.
Biological parent specimen(s)	Clinical Feature Checklist	:/Clinical Records		· See <u>Prer</u>	<u>natal Guid</u>	<u>lelines</u> for fu	urther ordering	g details
PERSON COMPLETING FORM		CONTACT (DIRECT PH	ONE OR EM	AIL)			DATE OF REQU	EST (MM/DD/YYYY)
	FETAL AN	ID MATERNA	L INFO	RMATI	ION			
LAST (FAMILY) NAME		MOTHER'S FIRST NAM	IE (FETUS O	F)		МІ	MOTHER'S DATE O	F BIRTH (MM/DD/YYYY)
MATERNAL ID CODE		FETAL SAMPLE TIME	AND DATE C	OLLECTED*			FETAL SEX	
		l⊓,	АМ ПРМ	MM/DD/YYY			∐ Male 	☐ Female ☐ Ambiguous
PRENATAL SPECIMEN SOURCE		TIME		MM/DD/YYY	Y		Based On:	
Cell Culture, Source	Fetal Blood (PUBS)	=					Based On.	
Direct Amniotic Fluid	Direct CVS	Other, Source						
approval letter if test is not NY state app						rk State Non-	Permitted Labora	tory Test Request
WILL A BACK-UP SAMPLE/CELL C				ICD-10 CO	DES or insurance b	oilling)	2	
	e is required for NGS and stro e include cell culture with vo		r other	1 PRIMARY		3/	3	
prendidi tests. Fieds		NAL MATERNA	I INFO					
MATERNAL SPECIMEN SOURCE	ADDITIO	NAL MAI ERNA	12 II1I O	DATE COL				
Whole Blood 5mL EDTA - Preferred	Saliva	☐ Buccal				ам Прм		
Extracted DNA, Source	Other, Source _			TIME			MM/DD/YYYY	
approval letter if test is not NY state app	STATE Inclued New York State proved. For a list of NY state ap	Genetic Testing Healtho proved tests, see website	are Provider <u>e</u> .	r Statement :	and New Yo	rk State Non-	Permitted Labora	tory Test Request
CLINICAL FEATURES		GEOANCESTRY / ETH		BLOOD TR	ANSFUSIO	N	BONE MARROW	TRANSPLANT
	Unknown			NO [_] Within la	ast 6 weeks	NO NI	ES, include date
Affected, features	AT PreventionGenetics?			DATE (MM/D	DD/YYYY)		DATE (MM/DD/YYY	Y)
				TYPE				
		PREGNANCY H	HISTOR	Ý				
GESTATIONAL AGE AT SAMPLE COLLECTION	ON	IS THIS AN ONGOING PREGNANCY?	DONOR PR	REGNANCY	MULTIPLE Twins	GESTATION PI Triplet		
	_ ☐ by U/S ☐ by LMP	□ No □ Yes	☐ Yes		Chorionic		Amnionicity	
D/	ATERNAL INFORI	MATION /Targo	tad Drana	atal Tastin	a Oply if	'noodod\		
LAST (FAMILY) NAME	RIERNAL INFORI	FIRST NAME	ted Prena	atai restin	ig Only, II	MI	DATE OF BIRTH	(MM/DD/YYYY)
PATERNAL SPECIMEN SOURCE				DATE COL	LECTED (MI	 M/DD/YYYY)*	PATIENT ID COI	DE
Whole Blood 5mL EDTA - Preferred	Saliva	☐ Buccal			,			
Extracted DNA, Source	Other, Source _							
SPECIMEN COLLECTED IN NEW YORK : approval letter if test is not NY state app	STATE Inclued New York State proved. For a list of NY state ap	Genetic Testing Healtho proved tests, see <u>website</u>	are Provider <u>e</u> .	r Statement :	and New Yo	rk State Non-	Permitted Labora	tory Test Request
CLINICAL FEATURES		GEOANCESTRY / ETH		BLOOD TR	ANSFUSION		BONE MARROW	TRANSPLANT
Unaffected Unknown Affected HAS PATIENT BEEN TESTED PREVIOUSLY AT I	•	<u>.]</u>		NO [] Within las	st 6 weeks	∐NO ∐YE	S, include date
	revention denetics:			DATE (MM/D	DD/YYYY)		DATE (MM/DD/YYY	Υ)
NO YES, PG ID#			TION	TYPE				
ADDITIONAL LAST (FAMILY) NAME	L FAMILY MEMB	FIRST NAME		「argeted F	Prenatal ⁻	Гesting On Г м і	ly, if needed) DATE OF BIRTH	(MM/DD/VVV)
EAST (FAMILITY NAME		TIRST NAME				'*''	DAIL OF BIRTH	(141141/202) 1 1 1 1 1
SPECIMEN SOURCE				DATE COL	LECTED () ()	4/00/00/04	DATIFALT ID COL	
Whole Blood 5mL EDTA - Preferred	d 🗍 Saliva	∏ Bu	ccal	DATE COL	LECTED (MI	M/DD/YYYY)*	PATIENT ID COI)E
Extracted DNA, Source	Other, So	urce						
	RELATIONSHIP TO FETUS	GEOANCESTRY / ETH	NICITY	I	ANSFUSIO	N	BONE MARROV	V TRANSPLANT
Unaffected Unknown				∐ NO	last Coos	ra inali:-l-:	NO □ VEC includ	
Affected, features HAS PATIENT BEEN TESTED PREVIOUSLY	AT DreventionConstics?	BIOLOGICAL SEX		- vvitnin	last 6 week	s, include:	YES, includ	e.
NO	AT Frevention defletics:	Male Femal	e	DATE (MM/D	DD/YYYY)		DATE (MM/DD/YYY	<u> </u>
YES, PG ID#		Other					DATE (MIM/DD/YYY	1)
		SPECIEV KA	ARYOTYPE	TYPE			1	

*If no collection date is provided, date of receipt will be used.

PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences Corporation.

>> PAGE 1 of 4



PreventionGenetics.com

PREVEN

			PATIENT	
	i	LAST NAME		
	ì	FIRST NAME		MI
ITIONGENETICS USE ONLY				

	CL	NICAL INFORM	MATION (REQUIR	ED)		
CLINICAL INDICATIO			☐ Fetal loss / stillbirth	-		
	sound (specify, attach re	eport if available)	_	fetal DNA test (specify)		
Family history: known familial variant testing (provide relationship,			Abnormal amniotic fluid AFP (specify level)			
copy of variant report, clinical details).			Other, specify, pleas	se call to discuss prior t	o submission	
Advanced maternal	lage (CMA only)					
			INFORMATION (REQ			
			etailed clinical notes/comp uality of clinical informatio			
pedigree. The ability to	interpret variants ance	ily correlates with the q	dunity of chillical informatio	ir provided. 🔲 elimedir	ccords attached.	
		TFST S	ELECTION			
			ETAL			
Please include any spec	ial instructions in the con	ments section. The test	s will be performed concurre	ently unless otherwise sp	ecified.	
If targeted testing, please specimen be sent for pre	e include details. For other natal testing. SEE <u>PRENAT</u>	tests, the Test Numbers ar <u>AL GUIDELINES</u> FOR MOF	nd Names can be obtained fro RE INFORMATION.	om our web site. We requi	re at least one parental	
EOD DDENATA			OR FILL IN DESIRED TEST			
TEST CODE	L EXOME TESTING	TEST NAME	E PRENATAL DIAGNOS	GENE(S)	VARIANT(S)	
	rgeted Prenatal Tes					
	ludes STAT turnaround ti		ontrol(s) required.			
	enatal Rapid CMA v					
995 Fe	tal Cell Culture* (onl	y available for testing per	formed at PreventionGenetic		R OPTIONS	
				Patient Only Family		
			L		or demographics (name, nip) on the proband report.	
				Patient Only Family	_ ,	
			L		or demographics (name, nip) on the proband report.	
ADDITIONAL ORDER INFORM	MATION			, ,		
		CDECIAL III	NCTRUCTIONS			
ADD EXOME-WIDE CN	IV ANALYSIS	SPECIAL II	NSTRUCTIONS	TESTING WILL BE RUN	CONCURRENTLY UNLESS	
\$250, CPT CODE 81479		Prenatal testing is alwa	ys run at a STAT priority . Please indicate below if	OTHERWISE NOTED		
With an order for any PGxome-base CNV analysis is available as an add of for your order, visit the panel-specif	on. To confirm if this is an option		t a standard TAT. Note: this	'	g, specify order above.	
Unavailable for PG-Select panels, Sa methods. To learn more, visit our we	anger sequencing, and other test	☐ No STAT, test at a st		No charge / No report		
		MAT	ΓERNAL			
Targeted Prenatal Testing	g (Test Code 990), positive	controls from parents an	d/or proband are required. Ma ered at no additional charge.	aternal Cell Contaminatio	n (MCC) Studies (Test Code	
TEST	strongly recommended to	GENE(S)	VARIANT(S)	REPORT WANTED?		
Positive Cor	ntrol for Variant(s)				, a targeted report for positive	
	200, or 300 - no charge	C) Cturdy		controls can be issued upor	request. YES NO	
Test Code 800 -	II Contamination (MC - no charge	.c, study				
5 7 . 18 . 17	.: (T 0 000)		ERNAL			
TEST	sting (Test Code 990), posit	GENE(S)	and/or proband are required. VARIANT(S)	REPORT WANTED?		
Positive Cor	ntrol for Variant(s)				g, a targeted report for positive	
lest Code 100, 2	200, or 300 - no charge	ADDITIONAL	FAMILY MEMBER	controls can be issued upor	request. YES NO	
For Targeted Prenatal Tes	sting (Test Code 990), posit		FAMILY MEMBER and/or proband are required.			
TEST		GENE(S)	VARIANT(S)	REPORT WANTED?	a a targeted report for modifica	
	ntrol for Variant(s) 200, or 300 - no charge			controls can be issued upor	g, a targeted report for positive request. YES NO	
	nce a specimen is receive	d.	l			



PreventionGenetics.com

PREVENTIONGENETICS USE ONLY

	PATIENT	
LAST NAME		
FIRST NAME		MI

PR	OVIDER / LABORATORY	CONTACT AND REPO	RTING	
	nethod of report transmission is dress, when possible. If you have			
	PROVIDER IN	NFORMATION		
NSTITUTION				
ADDRESS		CITY	STATE	ZIP
REQUESTING PHYSICIAN (First, Last, De	gree)	REQUESTING GENETIC COUNSELOR OR A	LLIED PROVIDER (First,	Last, Degree)
EMAIL ADDRESS (For report access via	myPrevent)	EMAIL ADDRESS (For report access via my	Prevent)	
PHONE NUMBER	NPI#	PHONE NUMBER	NPI#	
F YOU REQUIRE REPORTS TO BE TRAN	ISMITTED VIA ANOTHER SECURE METHOD, SPEC	IFY HERE.		
informed consent (as a applicable law and is o https://assets.preventiong to PreventionGenetics up and understand the risks,	are Provider, I certify that: (1) I have of applicable) to perform this test as of consistent, in all material respects, whenetics.com/documents/patient-inform poon request; (2) The patient and their far benefits, and limitations of this genetic number's (as applicable) consent for Preferonsent form.	documented on a signed conservith PreventionGenetics' Informed and consent.pdf), which I will main amily member (as applicable) have testing and the implications of the	ent form that co d Consent form tain on file and m e been appropriate e results; and (3) I I	omplies with (available at nake available ely counseled have received
		ABORATORY REPORT IS NEEDED		
NSTITUTION / CONTACT				
DDRESS		CITY	STATE	ZIP
EMAIL ADDRESS (For report access via	myPrevent)	PHONE NUMBER	NPI# (where applicab	ıle)
F YOU REQUIRE REPORTS TO BE TRAN	ISMITTED VIA ANOTHER SECURE METHOD, SPEC	IFY HERE.		
ADDITIONAL ACCESS TO REPORTS List	additional Healthcare Providers and their emails to	allow access to reports		
	INSTITUTIO	ON BILLING		
	WILL PROCEED WHEN ALL IF INSTITUTIONAL BILLING IS SEL et information above. Please provide	ECTED, PAGE 4 IS NOT REQUIRE		RECEIVED.
ILLING INSTITUTION			PO NUMBER	
ONTACT		PHONE NUMBER	EMAIL	
ADDRESS		CITY	STATE	ZIP
BILLING ACCOUNT NUMBER UPDATE	ED INFO	ACCESS TO TEST REPORT(S) FOR BILLING EMAIL ADDRESS		
EMAIL INVOICE VIA SECURE EMAIL (provis	do amail address	(For report access via myPrevent)		

OTHER (specify) _

PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences Corporation.



RESPONSIBLE PARTY'S NAME (MUST BE 18 YEARS OR OLDER)

Test information is available on our website: **PreventionGenetics.com**

	PATIENT	
LAST NAME		
FIRST NAME		МІ

PHONE NUMBER

COMPLETE THIS FORM FOR PATIENT PAY AND/OR INSURANCE BILLING

PATIENT TESTING WILL PROCEED WHEN ALL BILLING INFORMATION HAS BEEN RECEIVED.

** THIS SECTION MUST BE FILLED OUT COMPLETELY **

ADDRESS			CITY	STATE	ZIP
EMAIL					
A	CCEPTANCE of fina	ancial res	sponsibility for genetic te	esting	
	SIGNATURE REQUIR	ED BELO	W TO PROCEED WITH TESTI	NG.	
MY SIGNATURE INDICATES I ACC If applicable, I authorize PreventionGenetic genetic tests results, to my health plan / in services rendered. I understand my Health I customary rate limits, benefit exclusions, co full by my insurer, co-payments, and policy insurance claim issues. I understand my out- SIGN HERE: Required to	s to release information receisurance carrier and its Autho Plan / Insurance / Medicare / l verage limits, lack of authoriza deductibles except where m	ved including orized Repres Medicaid carr ation, medica ny liability is lir	, without limitation, medical informatic entatives. I further authorize insurance ier may not approve and reimburse my I necessity or otherwise. I understand I nited by contract or State and Federal I	on, which includes laborate e payments directly to Prev y medical genetic services i I am financially responsib aw. I agree to help Preventi	ory test results, such as entionGenetics for the n full due to usual and le for fees not paid in onGenetics resolve any
process form	IBLE PARTY SIGNATURE	<u></u>	RINTED NAME OF RESPONSIBLE PART	TY DATE	
	CDED		D DAVIJENT		
		DII CAI	RD PAYMENT		
 PATIENT PROMPT PAY (excludes Card information provided below will be cha 	•	The 10% Patie	ent Prompt Pay discount will apply		
PATIENT PAY - INSURANCE BILLII	•	THE 10% Facile	The Prompt Pay discount will apply.		
Card information provided below will be cha		ssed. The 10%	Patient Prompt Pay discount WILL NO	T apply.	
CREDIT CARD INFORMATION			. 5		
REDIT CARD NUMBER (VISA, DISCOVER, OR I	MASTERCARD ONLY)			EXPIRATION DATE	3-DIGIT SECURITY COD
SIGN HERE: Required to process credit card CREDIT CARD HOLDER:	S SIGNATURE			DATE	
	NCUDANCE INI	EODM/	ATION - IF APPLICA	DIE	
NDICATE THE TYPE OF INSURANCE					
	igned Tricare waiver	`	ARE include signed ABN form		PreventionGenetics.com network Medicaid plans.
POLICY HOLDER NAME	gried rineare riarrer		DATE OF BIRTH (MM/DD/YYYY)	RELATIONSHIP TO F	
PRIMARY INSURANCE COMPANY NAME (REQU	JIRED)			PHONE NUMBER	
POLICY ID#	GROUP #		AUTHORIZATION # Attach copy of au	Ithorization, PreventionGenetics m	oust be listed as servicing provide
SECONDARY INSURANCE	Insurance Card (both sides))			
	•				i.com
Prenatal testing will proceed whe the time-sensitive nature of mar	-		-		jiven
• To obtain required in-network pr	-	ting will b	te field for the following situ	actori omy.	
Indicate if testing should be held for					
For benefit investigation / pre-		re results v	with nationt directly via email	provided	
				LALLANILA CIA	
U Other:			·	·	



PreventionGenetics.com



All testing must be ordered by a qualified Healthcare Provider

>>>

A completed online order **OR** paper TRF and labeled specimen is required to initiate testing.

CLINICAL INFORMATION IS REQUIRED for PGnome®, PGxome®, and PGmax[™] panels.

Orders **MUST** include the completed clinical features checklist (preferred) or clinical notes/records. Completion of the checklist is strongly encouraged for all panel testing. The ability to interpret variants directly correlates with the quality of clinical information provided. Also include family medical history/pedigree, if available.

	CLIN	ICAL	FEATURES		
PERSON COMPLETING FORM		CONTACT (DIREC	CT PHONE OR EMAIL)		DATE OF REQUEST (MM/DD/YYYY)
LAST (FAMILY) NAME	PA	FIRST NAME	FORMATION EEN TESTED PREVIOUSLY AT PREVENTION	MI NGENETICS?	DATE OF BIRTH (MM/DD/YYYY) BIOLOGICAL SEX
		NO YES, PG ID#	-		Male Female Other
	CLINICAL INF	ORMATI	ON (CHECK ALL THAT APP	LY)	
PRE/PERINATAL Abnormality of septum pellucidum Absent septum pellucidum Cavum septum pellucidum Choroid plexus cyst (CPC) Absent nasal bone Congenital heart defect Intracardiac echogenic focus (IEF) Cystic hygroma Increased nuchal translucency, Size (mm): Pleural effusion Pericardial effusion Generalized edema Fetal ascites Hydrops fetalis Diaphragmatic hernia Absent stomach bubble Omphalocele Gastroschisis Echogenic bowel Fetal pyelectasis/hydronephrosis Decreased fetal movement Encephalocele Myelomeningocele/Spina bifida Sacrococcygeal teratoma Intrauterine growth retardation (IUGR) Small for gestational age (SGA) Oligohydramnios Polyhydramnios Short long bones Small thorax Fetal demise Prematurity, Gestational Age: Other:	STRUCTURAL BRAIL ABNORMALITIES / I Abnormal/delayed n Abnormality of basa Abnormality of brain Abnormality of white Periventricular Other: Abnormality of cerel Colpocephaly Hydrocephalus Ventriculomegaly Abnormality of corpinorphology: Agenesis Complete Partial Aplasia/hypoplasia overmis	MAGING nyelination ganglia stem e matter: pral ventricles: us callosum a f cerebellar f cerebellum mation: poplasia n orrhage ricular abnormality otopia	Cognitive impairment Delayed fine motor development Delayed gross motor development Developmental regression Gait disturbance Specify: Global developmental delay Hyperactivity Incoordination Intellectual disability Mild Moderate Severe/profound Learning disability Language impairment Absent speech Apraxia Articulation difficulties Delayed speech and languate development Expressive Receptive Dysarthria Echolalia Loss of speech Memory impairment Obsessive-compulsive behavior Self-injurious behavior: Biting Head-banging Skin picking Sensory processing disorder/neurodevelopmental abnormates Sleep disturbance Stereotypy Recurrent hand flapping Stereotypical hand wringing Other: NEUROLOGICAL Abnormality of nervous system Ataxia Athetosis		radykinesia erebral palsy norea pritical visual impairment ementia ysarthria yskinesia ysphagia ystonia ncephalopathy ait disturbance, pecify: eadache emiplegia ypotonia ypertonia fantile spasms igraine yoclonus europathy Peripheral Sensory arkinsonism/Parkinson Disease eizures, Type: pasticity yncope emors ertigo ther: MIOFACIAL/ MORPHISM ponormal facial shape, pecify: onormality of incisors, pecify: a nasi Cleft Thick Underdeveloped inteverted nares rachycephaly

PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences Corporation.





PreventionGenetics.com

	PATIENT	
LAST NAME		
FIRST NAME	N	41

PREVENTIONGENETICS USE ONLY

Chin abnormality, Specify:	☐ Microcephaly	EYES/VISION Age of onset of vision issues:	Macular abnormality, Specify:
Cleft lip:	☐ Micrognathia ☐ Nasal base abnormality:	Age of onset of vision issues:	Macular dystrophy
☐ Unilateral	Narrow	Esotropia	☐ Microphthalmia
Bilateral	☐ Wide	☐ Exotropia	Myopia
☐ Midline	Nasal bridge abnormality:	☐ Nystagmus	Ocular albinism
☐ Cleft palate: ☐ Unilateral	☐ Depressed ☐ Narrow	☐ Smooth pursuit ☐ Strabismus	☐ Optic atrophy
☐ Bilateral	☐ Prominent	Other:	Optic neuropathy
Midline	Short	Abnormality of vision,	Palpebral fissure abnormality:
Submucous cleft	Wide	Specify:	☐ Downslanted ☐ Upslanted
☐ Cloverleaf skull ☐ Columella abnormality:	☐ Nasal cartilage, absent	Abnormal anterior eye segment	Long
☐ Broad	☐ Nasal ridge abnormality:☐ Depressed	morphology Ablepharon	Short
High insertion	□ Depressed □ Narrow	Achromatopsia	☐ Almond-shaped
Low hanging	₩ide	☐ Aniridia	☐ Proptosis ☐ Ptosis
☐ Low insertion ☐ Short	☐ Nasal tip abnormality:	☐ Ankyloblepharon	☐ Retinal flecks
Craniosynostosis:	Bifid	☐ Anophthalmia	Retinal detachment
Coronal	☐ Broad ☐ Depressed	☐ Blepharochalasis	Retinitis pigmentosa
Lambdoidal	Deviated	☐ Blepharophimosis	Synophrys
Metopic	Narrow	☐ Cataracts	☐ Telecanthus
☐ Orbital ☐ Sagittal	Overhanging	Cataracts, congenital	Other:
☐ Dolichocephaly	☐ Nasolabial fold abnormality: ☐ Prominent	Coloboma	EARS/HEARING
Face abnormality:	☐ Underdeveloped	Corneal opacity	Age of onset of hearing loss:
Broad	☐ Neck abnormality:	☐ Corneal dystrophy ☐ Cone/cone-rod dystrophy	☐ Hearing impairment
Coarse facial features	Broad	☐ Cone/cone-rod dystrophy ☐ Congenital stationary night	Sensorineural
☐ Flat ☐ Long	Long	blindness	☐ Congenital ☐ Bilateral
□ Narrow	☐ Webbed ☐ Short	☐ Cryptophthalmos	Progressive
Round	Redundant nuchal skin	Deeply set eyes	☐ Conductive
Short	☐ Nose abnormality:	☐ Distichiasis	Congential
☐ Square ☐ Triangular	Absent	Dyschromatopsia (color	☐ Bilateral ☐ Progressive
Forehead abnormality:	☐ Bifid ☐ Long	blindness)	☐ Progressive
☐ Broad	□ Long □ Narrow	☐ Ectopia lentis	Anotia
Narrow	Prominent	☐ Ectropion ☐ Entropion	Abnormal newborn screen,
☐ Prominent ☐ Sloping	Short	☐ Entropion ☐ Epiblepharon	Specify:
☐ Sloping ☐ Creases	☐ Wide	☐ Epicanthus/epicanthal folds	Antihelix abnormality:
Frontal bossing	☐ Occiput abnormality: ☐ Flat	☐ Epicanthus inversus	☐ Absent ☐ Additional crus
☐ Jaw abnormality:	Prominent	☐ Eyebrow abnormality:	Angulated
Broad	☐ Plagiocephaly	Broad	☐ Inferior crus broad
Narrow	Philtrum abnormality:	☐ Highly arched ☐ Horizontal	☐ Inferior crus prominent
☐ Lip vermilion abnormality ☐ Lip abnormality:	Broad	Sparse	☐ Inferior crus underdeveloped☐ Superior crus prominent
Pit	☐ Deep ☐ Hypoplastic	☐ Thick	Superior crus underdeveloped
☐ Thin	Long	☐ Eyelash abnormality:	Antitragus abnormality:
Thick	Narrow	Absent	Absent
☐ Tented ☐ Exaggerated cupid's bow	☐ Smooth ☐ Short	☐ Long ☐ Prominent	☐ Bifid ☐ Everted
Absent cupid's bow	☐ Tented	Sparse	☐ Prominent
Malar abnormality:	☐ Proboscis	☐ Eyelid cleft	☐ Underdeveloped
Flattening	☐ Prognathism	☐ External ophthalmoplegia	☐ Ear abnormality:
☐ Prominence	☐ Retrognathia	Progressive	☐ Abnormality of the tragus☐ Auricular pit
☐ Midface abnormality:	☐ Scaphocephaly	Glaucoma	Crumpled
☐ Flat ☐ Prominence	Supraorbital ridge abnormality:	☐ Infraorbital abnormality: ☐ Crease	Cupped
Retrusion	☐ Prominent ☐ Underdeveloped	Fold	Long
Macrocephaly:	☐ Trigonocephaly	☐ Iris abnormality,	☐ Low-set ☐ Posteriorly rotated
☐ Relative ☐ True	Turricephaly	Specify:	Preauricular pit
☐ Irue ☐ Metopic suture abnormality:	Other:	☐ Lagophthalmos	Protruding
Depression		Leber optic atrophy	Short
Ridge		☐ Lens subluxation	☐ Satyr ☐ Tag



PreventionGenetics.com

PREVENTIONGENETICS USE ONLY

	PATIENT		
LAST NAME			
FIRST NAME		MI	
LIKS! HANNE		11411	

Helix abnormality: □ Lymphopenia □ Bradycardia GENITOURI □ Cleft / Notching □ Neutropenia □ Coarctation of the aorta □ Abnormal □ Crimped □ Pancytopenia □ Congenital heart defect Specify:	
☐ Cleft / Notching ☐ Neutropenia ☐ Coarctation of the aorta ☐ Abnormal	
LI CONCENTAL LI PADOVIONADIA LI L'ONGENITAL DESTRUCTO L'ADOCTOR	iity of the ateras,
Darwin notch Recurrent infections Dilated cardiomyopathy Ambiguou	uc genitalia
Darwin tubercle Severe combined Double outlet right ventricle Chordee	as gernitana
□ Notiching □ immunodeficiency □ □ Ebstein anomaly □ Countereb	idicm
Uverloided Thrembook tapania	
	d collecting system
- - - - - - - - - -	
□ Lobe abnormality: □ Hypertrophic cardiomyopathy □ Hydronep □ Cleft □ Abnormal blistering of the skip □ Mitral valve prolapse □ Hypospad	
E Abriornal blistering of the skin, D - mark tarre presupes D - typespas	lias/epispadias
- Specify. Thorseompaction cardiomyopathy in ingament	
Small Monormality of hall. Display Patent ductus arteriosus Display Micropent	
	c kidney dysplasia
Macrotia Disc. Disc.	
Other: Dalhinism Pulmonary hypertension Deliversion Deliversion	kidney disease
Renarage	nesis/hypoplasia
	eral agneisis
	al ageneisis eral hypoplasia
- Constant	al hypoplasia
Multiple Transposition of the great vessels	
Congenital adienal hypoplasia	
Collegentical adrenal rhyperplasia	terarremax
Delayed boile age	
Delayed publicity — Moscolos	
□ Diabetes insiplicus □ Dryckin □ GASTROINTESTINAL □ Abnormal	connective tissue
Diabetes Meliitus	l digit morphology
Typerandrogenism	
☐ Hemangioma ☐ Constipation: ☐ Clinod:	actvlv
Tryperpriospriatering Tryper	
Type triyotaisin	
Hypoglycemia Diarrhea Diarrhea Polyda	
Hypophosphatemia Diaphragmatic hernia Post	
☐ Hypothyroidism ☐ Posterior ☐ Duodenal stenosis/atresia ☐ Prea ☐ Increased cortisol level (Cushing) ☐ Low ☐ Esophageal stenosis/atresia ☐ Syndageal stenosis/atresia	
Bidate Distriction of the office of the offi	
□ Cmall c	
RESPIRATORY Hepatomegaly Barrel-	shaped
☐ Asthma ☐ Jacintate ☐ Hepatosplenomegaly ☐ Bell-sh	aped thorax
☐ Bronchiectasis ☐ Lipoma ☐ Inflammatory bowel disease ☐ Pectus	carinatum
Deline and lander of Lanceter de management	excavatum
Hyperventilation Palmoplantar keratoderma Liver disease Contractu	
	d muscle mass
☐ Converse to sign	
	ntolerance
Pulmonary fibrosis Vascular skin abnormality Pyloric stenosis Fatigue	
Respiratory insufficiency	
☐ Tracheomalacia ☐ Other: ☐ Tracheoesophageal fistula ☐ Hemihype	
☐ Tracheoesophageal fistula	
Other: Nasogastric Hypotonia	
HEMATOLOGIC/IMMUNOLOGIC A ortic root dilatation Gastrostomy Gastrostomy Gastrojejunal	ermobility
Agammaglobulinemia Arrhythmia Substitution Special Spe	
Alleraic rhinitis Atrial septal defect Limb shor	
Anemia Atrioventricular canal defect	
Hemolytic anemia Arrhythmogenic right ventricular	
Immunodeficiency dysplasia	rielic leal abnormalities:
Specify: Bicuspid aortic valve	
	<u></u>



PreventionGenetics.com

		PATIENT	
	LAST NAME		
	FIRST NAME		MI
EVENTIONGENETICS USE ONLY			

Myalgia Myopathic facies Myopathy Myelomeningocele/Spina Bifida/ Neural Tube Defect Osteoarthritis Osteoperosis Osteopenia Pain: Absent/decreased Abnormal sensation Episodic Limb Muscle Platyspondyly Recurrent fractures Rhabdomyolysis Rib abnormality: Cupped Fused Supernumerary Missing Short Spatulate	Rickets Scoliosis Short sta Skeletal Talipes Equir Othe Tall statu Thoracic Thumb a Addu Broac Triph. Vertebra Hemi Other: VASCULA Aneurys Aortic: Abdoo	ature dysplasia novarus r: ure dysplasia abnormality: cted d alangeal il bodies, abnormal form iia/hypoplasia erfly n vertebrae R SYSTEM m minal cting cic	Cerebral Other: Arterial calcification Arterial dissection Arterial tortuosity Arteriovenous malfo Epistaxis Lymphedema Pulmonary hyperte Arterial Vascular Stroke Other: Other: CHER TESTING Provide copy of report Echocardiogram: EEG: EMG/NCV: Biopsy: Gene testing: Results:	ormation nsion:	If you would like us to comment on the presence/absence of previously identified variants, provide a copy of the original report. Chromosomal Microarray (CMA): MRI brain: MRI (other): CT (other): Muscle biopsy: Ultrasound: X-Ray:
METABOLIC FINDINGS · Attach	relevant la				
Abnormal newborn screen Specify:			5		tabolic features
Abnormal metabolic profile					al cerebrospinal fluid (CSF)
(please check each metabolite outside non	mal limits)			-	al glycosylation
Acylcarnitine		Pterins		· -	
Acylglycines		Purines			al mitochondrial respiratory chain
Amino Acids		Pyrimidine		. │ │	nmonemia
Amylase		Pyruvate		.	lirubinemia
☐ Biotindase		Serum alpha fetoprot	ein (AFP)	.	
Carnitine		Sterols/Oxysterols		• -	ycemia
Cerebrospinal fluid		Transferrin		Hyperlip	oidemia
Coenyzme/enzyme activity		Uric acid		_ Hypogly	/cemia
Creatine phosphokinase (CPK)		☐ Very long chain fatty a	acids (VLCFA)	. Hypolipi	idemia
Essential fatty acids		Abnormal vitamin le		☐ Plasm	na
Folate		(please check each vitami normal limits)	in measuring outside	☐ Urine	
☐ Hepatic Transaminase				. │	cidosis
☐ Homocysteine		│			lic Acidosis
Hormones		_			
Ketones		☐ Vitamin B6			nalonic aciduria
Lactic acidosis					nalonic acidemia
		_			
Lipoproteins					
Lysosomal enzymes					



PREVENTIONGENETICS USE ONLY

	PATIENT		
LAST NAME			
FIRST NAME		MI	

Test information is available on our website:

PreventionGenetics.com

CANCER HISTORY Patient Information ■ No personal history ☐ Ovarian/Fallopian Tube / □ Pancreatic Other of cancer **Primary Peritoneal** Age of diagnosis: _ Age of diagnosis: ___ Age of diagnosis: _ Details: ___ □ Breast Prostate Age of diagnosis: _ □ Colorectal Age of diagnosis: __ ☐ Triple-Negative (ER, PR, Age of diagnosis: Metastatic Her2 negative) ☐ Yes ☐ No ☐ Unknown MSI/IHC results: DCIS (Ductal Carcinoma In Gleason Score Situ) ☐ Endometrial / Uterine **Polyps** ☐ DC (Invasive Ductal Age of diagnosis: ___ Age of diagnosis: _ Carcinoma) Number of polyps:_____ ☐ ILC (Invasive Lobular MSI/IHC results: Carcinoma) Pathology details: _____ ☐ Bilateral / >1 Primary **Family History of Cancer or Include Pedigree** ■ No known family history of cancer Limited Family Structure Limited family history available such as fewer than two female first or second-degree maternal or paternal relatives having lived beyond age 45 **Ashkenazi Jewish** □ NO YES, Maternal Yes, Paternal Unknown UNAVAILABLE RELATIVE IS FOR TESTING DECEASED PATIENT HAS NO CONTACT WITH WITH RELATIVE RELATIVE DECLINES TESTING AGE OF DIAGNOSIS **RELATION TO PATIENT** SELECT CANCER / POLYP TYPE / GLEASON SCORE ☐ Maternal Paternal ☐ Maternal ☐ Paternal П П Paternal Maternal П П

PEDIGREE

PAST FAMILY GENETIC TESTING NO previous testing in family. YES, Include Germline, Somatic or Tumor testing results. Describe or attach copies of report.

П

П

 \Box

Use this area to include a pedigree and/or additional relevant medical/family history.

VARIANT

Paternal
Maternal
Paternal

KNOWN FAMILIAL VARIANT: GENE